Abstract
Polyarteritis nodosa (PAN) is a rare vasculitis affecting middle-sized arteries. Its annual incidence in Europe is estimated to range between 0 and 1.6 cases per million, while the prevalence is about 31 cases per million. The frequency of hepatitis B virus (HBV)-related PAN has declined in developed countries since vaccination against HBV has been implemented. Specifically, before vaccination against HBV was implemented on a large scale, more than one-third of adults with PAN were infected by HBV, whereas currently only 5 % of European adults with PAN are infected by HBV. PAN is usually considered an immune-complex-driven vasculitis. However, the evidence of abundant CD4+ T cells in vascular inflammatory infiltrates suggests that PAN may also be induced by a T-cell response. Clinically, PAN usually presents with constitutional manifestations as well as symptoms and signs related to the organs affected. Organ ischemia is thought to be due to vascular stenoses, while ruptured aneurysms can result in tissue hemorrhage. The most frequent clinical features include constitutional manifestations, myalgia, arthralgia, peripheral neuropathy and mononeuritis multiplex. There are no specific blood tests to diagnose PAN, but inflammatory markers are typically elevated. Therefore, the diagnosis rests on histological changes in affected organs, showing a transmural vessel wall infiltrate, or angiographic findings, including small saccular or fusiform aneurysms and stenoses. Treatment includes glucocorticoids in patients without poor prognostic factors or cyclophosphamide if the disease is life- or organ-threatening.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kußmaul A, Maier R (1886) Über eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1:484–516
Ferrari E (1903) Über polyarteritis acuta nodosa (sogenannte Periarteritis nodosa) und ihre Beziehungen zur Polymyositis and Polyneuritis acuta. Beitr Pathol Anat 34:350–386
Dickson WEC (1908) Polyarteritis acuta nodosa and periarteritis nodosa. J Pathol 12:31–47
Wainwright J, Davson J (1950) The renal appearances in the microscopic form of periarteritis nodosa. J Pathol 62:189–196
Wohlwill F (1923) Über die nur mikroskopisch erkennbare Form der Periarteritis nodosa. Virchows Arch 246:377–411
Lightfoot RW Jr, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088–1093
Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192
Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11
Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227
Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798–806
Flores-Suarez LF, Contreras-Rodriguez FJ (2014) Critical appraisal of classification criteria for vasculitides. Curr Rheumatol Rep 16:422
Ishiguro N, Kawashima M (2010) Cutaneous polyarteritis nodosa: a report of 16 cases with clinical and histopathological analysis and a review of the published work. J Dermatol 37:85–93
Nakamura T, Kanazawa N, Ikeda T et al (2009) Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria. Arch Dermatol Res 301:117–121
Nakamura T, Tomoda K, Yamamura Y, Tsukano M, Honda I, Iyama K (2003) Polyarteritis nodosa limited to calf muscles: a case report and review of the literature. Clin Rheumatol 22:149–153
Dotan ZA, Laufer M, Heldenberg E et al (2003) Isolated testicular polyarteritis nodosa mimicking testicular neoplasm-long-term follow-up. Urology 62:352
Ebert EC, Hagspiel KD, Nagar M, Schlesinger N (2008) Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol 6:960–966
Mahr A, Guillevin L, Poissonnet M, Ayme S (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51:92–99
Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007) Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46:1329–1337
Pagnoux C, Cohen P, Guillevin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24:S71–S81
Pipitone N, Salvarani C (2008) The role of infectious agents in the pathogenesis of vasculitis. Best Pract Res Clin Rheumatol 22:897–911
Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC (2014) Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48–49:84–89
Pagnoux C, Seror R, Henegar C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62:616–626
Bonsib SM (2001) Polyarteritis nodosa. Semin Diagn Pathol 18:14–23
Pagnoux C, Mahr A, Cohen P, Guillevin L (2005) Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 84:115–128
Guillevin L, Lhote F, Gayraud M et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28
Ribi C, Cohen P, Pagnoux C et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186–1197
Guillevin L, Cohen P, Mahr A et al (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49:93–100
Langford CA (2001) Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: where do we stand? Arthritis Rheum 44:508–512
de MM, Mahr A (2011) Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 29:S110–S116
Guillevin L, Mahr A, Cohen P et al (2004) Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 51:482–487
Guillevin L, Mahr A, Callard P et al (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84:313–322
Segelmark M, Selga D (2007) The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol 19:33–38
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Pipitone, N., Salvarani, C. (2016). Polyarteritis Nodosa. In: Dammacco, F., Ribatti, D., Vacca, A. (eds) Systemic Vasculitides: Current Status and Perspectives. Springer, Cham. https://doi.org/10.1007/978-3-319-40136-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-40136-2_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40134-8
Online ISBN: 978-3-319-40136-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)